- Home
- PIII vs SNSE Comparison
PIII vs SNSE Comparison
Compare PIII & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | SNSE |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIII | SNSE |
|---|---|---|
| Price | $1.65 | $9.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $16.25 | ★ $72.50 |
| AVG Volume (30 Days) | 19.8K | ★ 93.4K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.75 | $5.00 |
| 52 Week High | $12.45 | $18.35 |
Technical Indicators
Market Signals| Indicator | PIII | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 20.17 | 46.98 |
| Support Level | $2.54 | $9.35 |
| Resistance Level | $2.63 | $10.45 |
| Average True Range (ATR) | 0.40 | 0.98 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 13.86 | 23.91 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).